Tuesday, December 10, 2024
wellness India Expo
Home Tags Appointment

Tag: Appointment

Bhushan Akshikar appointed as OPPI President

Bhushan is the Vice President & Managing Director of GSK (GlaxoSmithKline Pharmaceuticals) India

TrioTree Technologies appoints new COO and VP amid rapid expansion

Healthcare IT solutions provider names Divyesh J Sampat as COO and Mihir Jha as VP of Technology and Innovations, along with 15 new hires

Mandeep Singh Kumar appointed as the new Vice President & MD...

Assuming this position, he will oversee sales, marketing, and commercial operations for Medtronic’s business in India

Nakul Anand joins Paras Health Board as an Independent Director

With extensive experience in hospitality, Nakul Anand is set to enhance service quality and patient experience across Paras Health's hospitals

Lupin appoints Dr Ranjana Pathak as Chief Quality Officer

With over three decades of industry experience, Dr Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for Lupin’s global operations

Lupin appoints Christoph Funke as Chief Technical Operations Officer

He will be based in Mumbai and will oversee Lupin's Technical Operations function, integrating manufacturing, supply chain, and procurement

Veeda Clinical Research appoints Dr Mahesh Bhalgat as Group CEO

Prior to joining Veeda, Mahesh was the COO for Syngene International (Biocon Group Company), India’s largest CRO & CDMO company

Thermo Fisher Scientific appoints Srinath Venkatesh as its new MD for...

Under his leadership, the company is expected to continue its legacy of excellence and steer its operations in India to greater heights

CitiusTech appoints Sudhir Kesavan as Chief Operating Officer

In his new role, Sudhir will be instrumental in steering CitiusTech towards the execution of its strategic vision and ensuring unparalleled service delivery excellence

Zydus appoints Punit Patel as President & CEO to lead its...

Punit will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease portfolio